Skip to main content
OpenTrials
Completed

NCT Number: NCT02941172

CB1 Receptors in Human Brown Adipose Tissue

This study investigates cannabinoid CB1 receptors in human brown adipose tissue (BAT) and other tissues using positron emission tomography (PET) imaging. Subjects will be scanned in room temperature conditions and during controlled cold exposure, and the density of CB1 receptors in BAT and other tissues will be quantified. The investigators hypothesize, that cannabinoid signaling is increased in cold conditions, when BAT is metabolically active.

Understanding the mechanisms of BAT activation and the role of endocannabinoids in humans is important and beneficial in fighting against the epidemic of obesity and diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–60 year

Sex eligibility

Male

Study type

Interventional

Phase

Not applicable

Primary location

Turku PET Centre (Turku University Hospital)

Turku, 20521, Finland

About this study

Endocannabinoids have an important role in regulating energy balance and metabolism. Cannabinoid 1 receptors (CB1) are found in several tissues such as brown adipose tissue (BAT). Endocannabinoids and CB1 receptors participate in the control of lipid and glucose metabolism, and blockage of CB1 receptors has been found to improve metabolic factors linked to obesity and cardiovascular disease, making CB1 antagonists potential drugs against obesity and diabetes.

In this study the investigators use a PET radiotracer [18F]FMPEP-d2, which binds to CB1 receptors in vivo, to quantify the CB1 receptor density in BAT, white adipose tissue, muscle and the brain. This study is done once in warm conditions and once during controlled cold exposure. To verify whether the subject has metabolically active BAT, an additional PET scan with the radiotracer [18F]FDG is performed.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy volunteer
  • Group 1: BMI 20-26 kg/m2, Group2: BMI 27-40 kg/m2

Exclusion criteria

  • BMI < 20 kg/m2or BMI > 40 kg/m2
  • Any chronic disease that could affect the study outcome, including medicated type 2 diabetes
  • Mental disorder or poor compliance
  • Eating disorder or excessive use of alcohol, tobacco smoking or drug use
  • Past dose of radiation
  • Presence of any ferromagnetic objects that would make MR imaging contraindicated
  • Any other condition that in the opinion of the investigator could create a hazard to the subject safety, endanger the study procedures or interfere with the interpretation of study results

Treatment and study plan

Cold exposure

Other

Controlled cold exposure is performed before and during PET scan

[18F]FMPEP-d2

Other

PET radiotracer used in imaging

[18F]FDG

Other

PET radiotracer used in imaging

Primary outcomes

  1. CB1 density of brown adipose tissue acquired with PET

    Time frame: within one study day

    PET imaging is used to quantify CB1 receptors in tissues

Secondary outcomes

  1. Glucose uptake of brown adipose tissue acquired with PET

    Time frame: within one study day

    PET imaging is used to quantify glucose uptake in tissues

Sponsors and collaborators

Lead sponsor

Turku University Hospital

Other Gov

Registry information

Official study title

Cannabinoid CB1 Receptors in Human Brown Adipose Tissue

Acronym: CANBAT

Important dates

Study start
2015
Primary completion
2017
Study completion
2017
First posted
Oct 21, 2016
Registry last updated
Dec 20, 2018

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.